For peptide-based cancer vaccines to be efficacious, they must contain CD8+ epitopes to exploit the antigen cross-presentation pathway, leading to the activation of CTL anti-tumour immunity, along with CD4+ epitopes for T-helper cell activation, which sustains CTLs effector function (23). The gene discussed is CD4; the disease is neoplasm.